AI-generated analysis. Always verify with the original filing.
VivoSim Labs, a pharmaceutical and biotechnology services company, is conducting a best-efforts offering to raise capital for working capital and general corporate purposes, as it faces near-term liquidity constraints.
VivoSim Labs is conducting a capital raise under significant financial pressure, with disclosed cash reserves insufficient to fund operations beyond July 2026 without this offering. The company has transitioned from a clinical-stage biotechnology focus to a services model centered on 3D human tissue testing for drug toxicity prediction, leveraging proprietary technologies. This pivot follows the sale of its FXR program in March 2025. The offering mechanics are complex and carry notable investor risks. It is structured as a best-efforts offering with no minimum closing requirement, meaning the company could receive substantially less than the maximum $4 million target. The offering is split into two tranches, with the second $1 million tranche contingent on specific stock price and trading volume conditions that may not be met. The securities package includes common stock (or pre-funded warrants) bundled with common warrants, which contain a cashless exercise feature. This feature, based on a Black-Scholes valuation model, could force the issuance of a significantly higher number of shares if the stock price is low at exercise, leading to substantial dilution. The company acknowledges it will likely not receive additional funds from warrant exercises due to this structure. The intended use of proceeds is broad and discretionary, earmarked for working capital and general corporate purposes. Management has wide latitude in deploying the funds, which may not enhance shareholder value. The lack of a trading market for the warrants further limits liquidity for investors. The company's financial profile is characterized by ongoing losses and an accumulated deficit of $350.2 million, underscoring the critical nature of this financing for its continued operation.
Offering Amount
$1.22B
Shares Offered
720,709,479
Price Range
$1.69 – $1.69
Shares Offered
2,366,862
Offering Amount
Up to $4,000,000
Share Type
Common Stock (or Pre-Funded Warrants in lieu thereof)
Exchange
NASDAQ
Ticker
VIVS
Use of Proceeds: Working capital and general corporate purposes, which could include capital expenditures, research and development expenditures, regulatory affairs expenditures, legal expenditures, acquisitions of new technologies and investments and business combinations.
A pharmaceutical and biotechnology services company focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine.